Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Back to research

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

2017583 citationsJournal Article

Authors

Andrew A. Wylie · Novartis (United States)

Joseph Schoepfer · Novartis (Switzerland)

Wolfgang Jahnke · Novartis Institutes for BioMedical Research

Sandra W. Cowan‐Jacob · Novartis Institutes for BioMedical Research

Alice Loo · Novartis (United States)

Pascal Furet · Novartis (Switzerland)

Andreas L. Marzinzik

Topics & Keywords

Chronic Myeloid Leukemia Treatments Eosinophilic Disorders and Syndromes Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Nature

Volume 543, Issue 7647, pp. 733-737

DOI: 10.1038/nature21702

Field-Weighted Citation Impact: 34.17

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Researchclopedia

· Novartis (Switzerland)

Xavier Pellé · Novartis (Switzerland)

Jerry Donovan · Novartis (United States)

Wenjing Zhu · Novartis (United States)

Silvia Buonamici · Novartis (United States)

Amr Hassan · Novartis (United States)

Franco Lombardo · Novartis (United States)

Varsha Iyer · Novartis Institutes for BioMedical Research

Michael R. Palmer · Novartis (United States)

Giuliano Berellini · Novartis (United States)

Stephanie Dodd · Novartis (United States)

Sanjeev Thohan · Novartis (United States)

Hans Bitter · Novartis (United States)

Susan Branford · Centre for Cancer Biology

David M. Ross · South Australia Pathology

Timothy P. Hughes · South Australian Health and Medical Research Institute

Lilli Petruzzelli · Novartis (United States)

K. Gary J. Vanasse · Novartis (United States)

Markus Warmuth · Novartis (United States)

Francesco Hofmann · Novartis (Switzerland)

Nicholas Keen · Novartis (United States)

William R. Sellers · Novartis (United States)